Spots Global Cancer Trial Database for A Study of SGN-CD228A in Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of SGN-CD228A in Advanced Solid Tumors
Official Title: A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
Study ID: NCT04042480
Interventions
Study Description
Brief Summary: This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
Detailed Description: This study is designed to evaluate the safety, tolerability, PK, and antitumor activity of SGN-CD228A in select advanced solid tumors. The study will include dose escalation and dose expansion, with multiple disease-specific expansion cohorts.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
The Angeles Clinic and Research Institute, Los Angeles, California, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Wake Forest Baptist Medical Center / Wake Forest University, Winston-Salem, North Carolina, United States
Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Sanford Cancer Center, Sioux Falls, South Dakota, United States
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Institut Gustave Roussy, Villejuif Cedex, , France
Istituto Europeo di Oncologia, Milano, , Italy
Hospital Universitario Vall d'Hebron, Barcelona, , Spain
The Royal Marsden Hospital (Surrey), Sutton, , United Kingdom
Contact Details
Name: Anu Gupta, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
